Research tool page — not in the public editorial index
This company can still be explored inside Wall Street Score, but this URL remains noindex and is not eligible for Google-served ads until source-specific publisher curation is documented and the public research-quality checks pass.
Radiopharm Theranostics Limited
RADX · Price history
Price at last available close
$1.19
−$0.43 (-26.54%) 1M
2026-10-30
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Radiopharm Theranostics Limited
Primary reporting period: 2026-06-30 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers).
How they make money
Radiopharm Theranostics is a clinical-stage radiopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on the research, development, and clinical testing of a pipeline of radiopharmaceutical products for diagnostic and therapeutic applications, funded primarily through capital raises and strategic partnerships.
Products & services
The company develops a pipeline of radiopharmaceutical candidates including RAD 101 (for brain metastases), RAD 204 (for solid tumors), and BetaBart (RV-01).
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Healthcare providers and clinical research institutionsSource
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Research Organizations (CROs) — The company engages various third-party CROs to manage and conduct its clinical trials.Source
Competitors
Strengths
- Diverse pipeline of radiopharmaceutical assetsSource
Sources
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
31
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
28
Poor
Financial Strength
66
Business Quality / Moat
0
Management
40
Growth Quality
0
Risk / Durability
6
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
24
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
34/100
Building Historical Record
Model Score 34/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Balance-sheet / debt profile scores strongly
- •Debt service risk
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
Company-specific research
Questions worth answering for RADX
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •What is driving RADX's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
- •How is RADX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for RADX to reach sustainable profitability?
- •What future growth or profitability would be needed to justify RADX's current valuation?
- •What does the current share basis reconciled warning mean for the reliability or interpretation of RADX's score?
Essential Investment Snapshot
Wall Street Score
31
Opportunity Score
24
Market Cap
$1.5M
P/E Ratio
-0.0
EPS
$-29.22
52-Week High
$16.25
52-Week Low
$1.00
Beta
0.80
Analyst Target
$6.00
Shares Outstanding
1.3M
Total Revenue
$1.9M
Total Debt
$0
Dividend
No current dividend
Liquidation Value / Share
$12.09
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Weakening momentum
Extreme movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for RADX
Detected from reported data — verify before acting.Debt service risk
Interest coverage is low (~-607.9x). Earnings may be strained to cover interest expense.
Community Sentiment
0 active · 0 total callsNo personal call yet on RADX.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Diverse pipeline of radiopharmaceutical assets.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −History of operating losses and dependence on future capital raises.
- −Uncertainty of clinical trial success and regulatory approval.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
7 historical score records availablePrevious Score
30
Oct 1, 2026
Change
+0.3
points
Current Score
31
Oct 15, 2026
Category Changes
RADX increased 0.3 points because Revenue improved by 3.3 points.
Positive Contributors
- + Revenue improved by 3.3 points
Projected Score
Projected Score
24
Projected Change
-6.4 points
Preliminary comparable-period financial changes suggest decline of approximately 6.4 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$1.19
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Revenue | — | $1.9M | $2.5M | $209K | ···· | ···· |
| Cost of Revenue | — | $3.4M | $2.5M | $0.00 | ···· | ···· |
| Gross Profit | — | -$1.5M | $27K | $209K | ···· | ···· |
| Research & Development | — | $0.00 | $19.2M | $12.3M | ···· | ···· |
| SG&A Expenses | — | $11.1M | $11.5M | $10.6M | ···· | ···· |
| Operating Expenses | — | $45.2M | $26.7M | $25.8M | ···· | ···· |
| EBITDA | — | -$44.7M | -$24.8M | -$30.8M | ···· | ···· |
| Operating Income | — | -$46.6M | -$26.6M | -$25.6M | ···· | ···· |
| Interest Expense | — | $77K | $46K | $449K | ···· | ···· |
| Income Before Tax | — | -$38.8M | -$26.7M | -$33.4M | ···· | ···· |
| Income Tax Expense | — | -$37K | $72K | $67K | ···· | ···· |
| Net Income | — | -$37.6M | -$26.8M | -$33.5M | ···· | ···· |
| Basic EPS | — | $-3.18 | $-3.68 | $-25.12 | ···· | ···· |
| Basic Shares | 39.4K | 11.81M | 6.94M | 1.29M | ···· | ···· |
| Diluted Shares | 39.4K | 11.81M | 6.94M | 1.29M | ···· | ···· |
Earnings Summary
Revenue
$978254
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$508.72
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
Not available
Cash Change
-88.0%
Margin Change
-92.6 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Weakened
- Margins contracted
- Cash position declined
Potential Score Impact
Positive indicators included revenue growth, EPS growth. Pressure indicators included cash levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 3.1%. EPS increased 8.0%. Cash declined 88.0%. Net income margin declined by 92.6 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
7 historical recordsHistorical Score Chart
3 of 7 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma
Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors
Radiopharm Theranostics (NASDAQ:RADX) Trading Down 8.4% – What’s Next?
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial
Rumor Mill · RADX
Corporate developments & opportunities
No reviewed developments match this filter.
The reliability percentage measures the strength of the supporting evidence—not the probability that the event will occur or that the stock will rise. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial